ЭФФЕКТИВНОСТЬ ПОСЛЕОПЕРАЦИОННОЙ ПРОТИВОРЕЦИДИВНОЙ ТЕРАПИИ АДАЛИМУМАБОМ И АЗАТИОПРИНОМ ПРИ БОЛЕЗНИ КРОНА

INTRODUCTION. About 75% of patients with Crohn's disease (CD) required surgery due to the complications of CD. Surgical treatment does not cure this disease. The question of appropriate therapy for the prevention of postoperative reccurence of CD remains open until now. The purpose of this study was to compare immunosuppressive and biological therapy as a postoperative preventive therapy. MATERIALS AND METHODS. 91 patients with CD who underwent surgery in the A.N. Ryzhykh State Scientific Center for Coloproctology of the Ministry of Health of Russian Federation from 2010 to 2017 were included in the study. Patients who had inflammation in the remaining areas of the intestine in the outcome of surgical treatment were excludedfrom the study. After surgery, patients were randomized into 3 groups. In the first group preventive therapy was carried out with azathioprine, in the second group with adalimumab, in the third group, patients received combination therapy with azathioprine and adalimumab. Clinical, endoscopical and laboratory assessment of disease activity was conducted at 3, 6 and 12 month after the surgery. RESULTS. During one year of preventive therapy with azathioprine, adalimumab, or a combination of this medications, relapse occurred in 17 patients (17/83, 20%). There were no statistically significant differences between the groups in any of the stages of evaluation. CONCLUSION: The data obtained in the study allow to conclude that the frequency of relapses of CD on postoperative preventive therapy does not depend on the specific drug, as well as on demographic and anamnestic parameters.